2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
To evaluate the feasibility of (1) the use of the Beter Voorbereid* application and the study procedures of a randomized controlled trial (finished in June 2019) and (2) evaluating the effectiveness of the *Beter Voorbereid* application on improved…